Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 7,147,000 | 6,018,000 | 3,977,000 | 1,868,000 | 12,800,000 |
| Depreciation Amortization | 5,788,000 | 3,840,000 | 2,467,000 | N/A | 5,217,000 |
| Income taxes - deferred | 1,793,000 | 1,163,000 | 797,000 | -400,000 | 1,295,000 |
| Accounts receivable | -980,000 | N/A | N/A | N/A | -544,000 |
| Accounts payable and accrued liabilities | 553,000 | N/A | N/A | N/A | 252,000 |
| Other Working Capital | 199,000 | -1,852,000 | -2,308,000 | -1,291,000 | 576,000 |
| Other Operating Activity | -875,000 | 916,000 | 590,000 | 2,235,000 | -5,324,000 |
| Operating Cash Flow | $13,625,000 | $10,085,000 | $5,523,000 | $2,412,000 | $14,272,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2,333,000 | 2,306,000 | 2,308,000 | 2,314,000 | -1,968,000 |
| PPE Investments | -522,000 | -109,000 | 251,000 | -118,000 | -1,152,000 |
| Net Acquisitions | -4,925,000 | -4,948,000 | -1,490,000 | -521,000 | -14,684,000 |
| Purchase Of Investment | -302,000 | -223,000 | -154,000 | -109,000 | 12,649,000 |
| Sale Of Investment | 1,152,000 | 742,000 | 177,000 | 35,000 | 165,000 |
| Purchase Sale Intangibles | 95,000 | -282,000 | -217,000 | -266,000 | -571,000 |
| Other Investing Activity | 38,000 | -312,000 | -238,000 | -273,000 | -601,000 |
| Investing Cash Flow | $-2,226,000 | $-2,544,000 | $854,000 | $1,328,000 | $-5,591,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -1,582,000 | -519,000 | -942,000 | -149,000 | 1,687,000 |
| Debt Issued | 93,000 | 93,000 | N/A | N/A | 2,856,000 |
| Debt Repayment | -3,195,000 | -3,194,000 | -3,008,000 | -3,001,000 | -366,000 |
| Common Stock Issued | 201,000 | 205,000 | 200,000 | N/A | N/A |
| Common Stock Repurchased | -5,533,000 | -5,530,000 | -2,590,000 | -222,000 | -2,036,000 |
| Dividend Paid | -6,645,000 | -6,645,000 | -6,645,000 | -6,645,000 | -6,966,000 |
| Other Financing Activity | 3,034,000 | 3,166,000 | 3,274,000 | 334,000 | 581,000 |
| Financing Cash Flow | $-13,627,000 | $-12,424,000 | $-9,711,000 | $-9,683,000 | $-4,244,000 |
| Exchange Rate Effect | 69,000 | -10,000 | 54,000 | -22,000 | -26,000 |
| Beginning Cash Position | 13,271,000 | 13,271,000 | 13,271,000 | 13,271,000 | 8,860,000 |
| End Cash Position | 11,112,000 | 8,378,000 | 9,991,000 | 6,807,000 | 13,271,000 |
| Net Cash Flow | $-2,159,000 | $-4,893,000 | $-3,280,000 | $-6,464,000 | $4,411,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 13,625,000 | 10,085,000 | 5,523,000 | 2,412,000 | 14,272,000 |
| Capital Expenditure | -1,379,000 | -918,000 | -561,000 | -282,000 | -1,254,000 |
| Free Cash Flow | 12,246,000 | 9,167,000 | 4,962,000 | 2,130,000 | 13,018,000 |